

Global Biologics and Biosimilars Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030

<https://marketpublishers.com/r/GD05777795DAEN.html>

Date: April 2024

Pages: 207

Price: US\$ 4,250.00 (Single User License)

ID: GD05777795DAEN

Abstracts

Summary

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.

A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.

According to APO Research, The global Biologics and Biosimilars market is projected to grow from US\$ million in 2024 to US\$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

North American market for Biologics and Biosimilars is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Biologics and Biosimilars is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Biologics and Biosimilars is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Biologics and Biosimilars is estimated to increase from \$ million in 2024 to reach \$ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global manufacturers of Biologics and Biosimilars include Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly and Novartis, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Biologics and Biosimilars, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Biologics and Biosimilars, also provides the sales of main regions and countries. Of the upcoming market potential for Biologics and Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biologics and Biosimilars sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Biologics and Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Biologics and Biosimilars sales, projected growth trends, production technology, application and end-user industry.

Biologics and Biosimilars segment by Company

Roche

Amgen

AbbVie

Sanofi-Aventis

Johnson & Johnson

Pfizer

Novo Nordisk

Eli Lilly

Novartis

Merck

3sbio

Changchun High Tech

CP Guojian

Biotech

Gelgen

Innovent

Dong Bao

Ganlee

United Laboratories

Biologics and Biosimilars segment by Type

Monoclonal Antibodies

Interferon

Erythropoietin

Insulin

Vaccines

Others

Biologics and Biosimilars segment by Application

Tumor

Diabetes

Cardiovascular

Hemophilia

Others

Biologics and Biosimilars segment by Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Biologics and Biosimilars status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Biologics and Biosimilars market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Biologics and Biosimilars significant trends, drivers, influence factors in global and regions.
6. To analyze Biologics and Biosimilars competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers,

restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biologics and Biosimilars market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2019-2030).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biologics and Biosimilars industry.

Chapter 3: Detailed analysis of Biologics and Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Biologics and Biosimilars in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

Contents

1 MARKET OVERVIEW

- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
 - 1.2.1 Global Biologics and Biosimilars Sales Value (2019-2030)
 - 1.2.2 Global Biologics and Biosimilars Sales Volume (2019-2030)
 - 1.2.3 Global Biologics and Biosimilars Sales Average Price (2019-2030)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives

2 BIOLOGICS AND BIOSIMILARS MARKET DYNAMICS

- 2.1 Biologics and Biosimilars Industry Trends
- 2.2 Biologics and Biosimilars Industry Drivers
- 2.3 Biologics and Biosimilars Industry Opportunities and Challenges
- 2.4 Biologics and Biosimilars Industry Restraints

3 BIOLOGICS AND BIOSIMILARS MARKET BY COMPANY

- 3.1 Global Biologics and Biosimilars Company Revenue Ranking in 2023
- 3.2 Global Biologics and Biosimilars Revenue by Company (2019-2024)
- 3.3 Global Biologics and Biosimilars Sales Volume by Company (2019-2024)
- 3.4 Global Biologics and Biosimilars Average Price by Company (2019-2024)
- 3.5 Global Biologics and Biosimilars Company Ranking, 2022 VS 2023 VS 2024
- 3.6 Global Biologics and Biosimilars Company Manufacturing Base & Headquarters
- 3.7 Global Biologics and Biosimilars Company, Product Type & Application
- 3.8 Global Biologics and Biosimilars Company Commercialization Time
- 3.9 Market Competitive Analysis
 - 3.9.1 Global Biologics and Biosimilars Market CR5 and HHI
 - 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
 - 3.9.3 2023 Biologics and Biosimilars Tier 1, Tier 2, and Tier
- 3.10 Mergers & Acquisitions, Expansion

4 BIOLOGICS AND BIOSIMILARS MARKET BY TYPE

- 4.1 Biologics and Biosimilars Type Introduction
 - 4.1.1 Monoclonal Antibodies

- 4.1.2 Interferon
- 4.1.3 Erythropoietin
- 4.1.4 Insulin
- 4.1.5 Vaccines
- 4.1.6 Others
- 4.2 Global Biologics and Biosimilars Sales Volume by Type
 - 4.2.1 Global Biologics and Biosimilars Sales Volume by Type (2019 VS 2023 VS 2030)
 - 4.2.2 Global Biologics and Biosimilars Sales Volume by Type (2019-2030)
 - 4.2.3 Global Biologics and Biosimilars Sales Volume Share by Type (2019-2030)
- 4.3 Global Biologics and Biosimilars Sales Value by Type
 - 4.3.1 Global Biologics and Biosimilars Sales Value by Type (2019 VS 2023 VS 2030)
 - 4.3.2 Global Biologics and Biosimilars Sales Value by Type (2019-2030)
 - 4.3.3 Global Biologics and Biosimilars Sales Value Share by Type (2019-2030)

5 BIOLOGICS AND BIOSIMILARS MARKET BY APPLICATION

- 5.1 Biologics and Biosimilars Application Introduction
 - 5.1.1 Tumor
 - 5.1.2 Diabetes
 - 5.1.3 Cardiovascular
 - 5.1.4 Hemophilia
 - 5.1.5 Others
- 5.2 Global Biologics and Biosimilars Sales Volume by Application
 - 5.2.1 Global Biologics and Biosimilars Sales Volume by Application (2019 VS 2023 VS 2030)
 - 5.2.2 Global Biologics and Biosimilars Sales Volume by Application (2019-2030)
 - 5.2.3 Global Biologics and Biosimilars Sales Volume Share by Application (2019-2030)
- 5.3 Global Biologics and Biosimilars Sales Value by Application
 - 5.3.1 Global Biologics and Biosimilars Sales Value by Application (2019 VS 2023 VS 2030)
 - 5.3.2 Global Biologics and Biosimilars Sales Value by Application (2019-2030)
 - 5.3.3 Global Biologics and Biosimilars Sales Value Share by Application (2019-2030)

6 BIOLOGICS AND BIOSIMILARS MARKET BY REGION

- 6.1 Global Biologics and Biosimilars Sales by Region: 2019 VS 2023 VS 2030
- 6.2 Global Biologics and Biosimilars Sales by Region (2019-2030)
 - 6.2.1 Global Biologics and Biosimilars Sales by Region: 2019-2024
 - 6.2.2 Global Biologics and Biosimilars Sales by Region (2025-2030)

- 6.3 Global Biologics and Biosimilars Sales Value by Region: 2019 VS 2023 VS 2030
- 6.4 Global Biologics and Biosimilars Sales Value by Region (2019-2030)
 - 6.4.1 Global Biologics and Biosimilars Sales Value by Region: 2019-2024
 - 6.4.2 Global Biologics and Biosimilars Sales Value by Region (2025-2030)
- 6.5 Global Biologics and Biosimilars Market Price Analysis by Region (2019-2024)
- 6.6 North America
 - 6.6.1 North America Biologics and Biosimilars Sales Value (2019-2030)
 - 6.6.2 North America Biologics and Biosimilars Sales Value Share by Country, 2023 VS 2030
- 6.7 Europe
 - 6.7.1 Europe Biologics and Biosimilars Sales Value (2019-2030)
 - 6.7.2 Europe Biologics and Biosimilars Sales Value Share by Country, 2023 VS 2030
- 6.8 Asia-Pacific
 - 6.8.1 Asia-Pacific Biologics and Biosimilars Sales Value (2019-2030)
 - 6.8.2 Asia-Pacific Biologics and Biosimilars Sales Value Share by Country, 2023 VS 2030
- 6.9 Latin America
 - 6.9.1 Latin America Biologics and Biosimilars Sales Value (2019-2030)
 - 6.9.2 Latin America Biologics and Biosimilars Sales Value Share by Country, 2023 VS 2030
- 6.10 Middle East & Africa
 - 6.10.1 Middle East & Africa Biologics and Biosimilars Sales Value (2019-2030)
 - 6.10.2 Middle East & Africa Biologics and Biosimilars Sales Value Share by Country, 2023 VS 2030

7 BIOLOGICS AND BIOSIMILARS MARKET BY COUNTRY

- 7.1 Global Biologics and Biosimilars Sales by Country: 2019 VS 2023 VS 2030
- 7.2 Global Biologics and Biosimilars Sales Value by Country: 2019 VS 2023 VS 2030
- 7.3 Global Biologics and Biosimilars Sales by Country (2019-2030)
 - 7.3.1 Global Biologics and Biosimilars Sales by Country (2019-2024)
 - 7.3.2 Global Biologics and Biosimilars Sales by Country (2025-2030)
- 7.4 Global Biologics and Biosimilars Sales Value by Country (2019-2030)
 - 7.4.1 Global Biologics and Biosimilars Sales Value by Country (2019-2024)
 - 7.4.2 Global Biologics and Biosimilars Sales Value by Country (2025-2030)
- 7.5 USA
 - 7.5.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
 - 7.5.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
 - 7.5.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030

2030

7.6 Canada

7.6.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)

7.6.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030

7.6.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS

2030

7.7 Germany

7.7.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)

7.7.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030

7.7.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS

2030

7.8 France

7.8.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)

7.8.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030

7.8.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS

2030

7.9 U.K.

7.9.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)

7.9.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030

7.9.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS

2030

7.10 Italy

7.10.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)

7.10.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030

7.10.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS

2030

7.11 Netherlands

7.11.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)

7.11.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030

7.11.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS

2030

7.12 Nordic Countries

7.12.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)

7.12.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030

7.12.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS

2030

7.13 China

7.13.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)

7.13.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030

7.13.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030

7.14 Japan

7.14.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)

7.14.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030

7.14.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030

7.15 South Korea

7.15.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)

7.15.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030

7.15.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030

7.16 Southeast Asia

7.16.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)

7.16.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030

7.16.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030

7.17 India

7.17.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)

7.17.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030

7.17.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030

7.18 Australia

7.18.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)

7.18.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030

7.18.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030

7.19 Mexico

7.19.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)

7.19.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030

7.19.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030

7.20 Brazil

7.20.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)

7.20.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030

7.20.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030

7.21 Turkey

7.21.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)

- 7.21.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
- 7.21.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
- 7.22 Saudi Arabia
 - 7.22.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
 - 7.22.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
 - 7.22.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030
- 7.23 UAE
 - 7.23.1 Global Biologics and Biosimilars Sales Value Growth Rate (2019-2030)
 - 7.23.2 Global Biologics and Biosimilars Sales Value Share by Type, 2023 VS 2030
 - 7.23.3 Global Biologics and Biosimilars Sales Value Share by Application, 2023 VS 2030

8 COMPANY PROFILES

8.1 Roche

- 8.1.1 Roche Company Information
- 8.1.2 Roche Business Overview
- 8.1.3 Roche Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
- 8.1.4 Roche Biologics and Biosimilars Product Portfolio
- 8.1.5 Roche Recent Developments

8.2 Amgen

- 8.2.1 Amgen Company Information
- 8.2.2 Amgen Business Overview
- 8.2.3 Amgen Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
- 8.2.4 Amgen Biologics and Biosimilars Product Portfolio
- 8.2.5 Amgen Recent Developments

8.3 AbbVie

- 8.3.1 AbbVie Company Information
- 8.3.2 AbbVie Business Overview
- 8.3.3 AbbVie Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
- 8.3.4 AbbVie Biologics and Biosimilars Product Portfolio
- 8.3.5 AbbVie Recent Developments

8.4 Sanofi-Aventis

- 8.4.1 Sanofi-Aventis Company Information
- 8.4.2 Sanofi-Aventis Business Overview
- 8.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)

- 8.4.4 Sanofi-Aventis Biologics and Biosimilars Product Portfolio
- 8.4.5 Sanofi-Aventis Recent Developments
- 8.5 Johnson & Johnson
 - 8.5.1 Johnson & Johnson Company Information
 - 8.5.2 Johnson & Johnson Business Overview
 - 8.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
 - 8.5.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
 - 8.5.5 Johnson & Johnson Recent Developments
- 8.6 Pfizer
 - 8.6.1 Pfizer Company Information
 - 8.6.2 Pfizer Business Overview
 - 8.6.3 Pfizer Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
 - 8.6.4 Pfizer Biologics and Biosimilars Product Portfolio
 - 8.6.5 Pfizer Recent Developments
- 8.7 Novo Nordisk
 - 8.7.1 Novo Nordisk Company Information
 - 8.7.2 Novo Nordisk Business Overview
 - 8.7.3 Novo Nordisk Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
 - 8.7.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
 - 8.7.5 Novo Nordisk Recent Developments
- 8.8 Eli Lilly
 - 8.8.1 Eli Lilly Company Information
 - 8.8.2 Eli Lilly Business Overview
 - 8.8.3 Eli Lilly Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
 - 8.8.4 Eli Lilly Biologics and Biosimilars Product Portfolio
 - 8.8.5 Eli Lilly Recent Developments
- 8.9 Novartis
 - 8.9.1 Novartis Company Information
 - 8.9.2 Novartis Business Overview
 - 8.9.3 Novartis Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
 - 8.9.4 Novartis Biologics and Biosimilars Product Portfolio
 - 8.9.5 Novartis Recent Developments
- 8.10 Merck
 - 8.10.1 Merck Company Information
 - 8.10.2 Merck Business Overview
 - 8.10.3 Merck Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
 - 8.10.4 Merck Biologics and Biosimilars Product Portfolio

- 8.10.5 Merck Recent Developments
- 8.11 3sbio
 - 8.11.1 3sbio Company Information
 - 8.11.2 3sbio Business Overview
 - 8.11.3 3sbio Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
 - 8.11.4 3sbio Biologics and Biosimilars Product Portfolio
 - 8.11.5 3sbio Recent Developments
- 8.12 Changchun High Tech
 - 8.12.1 Changchun High Tech Company Information
 - 8.12.2 Changchun High Tech Business Overview
 - 8.12.3 Changchun High Tech Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
 - 8.12.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
 - 8.12.5 Changchun High Tech Recent Developments
- 8.13 CP Guojian
 - 8.13.1 CP Guojian Company Information
 - 8.13.2 CP Guojian Business Overview
 - 8.13.3 CP Guojian Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
 - 8.13.4 CP Guojian Biologics and Biosimilars Product Portfolio
 - 8.13.5 CP Guojian Recent Developments
- 8.14 Biotech
 - 8.14.1 Biotech Company Information
 - 8.14.2 Biotech Business Overview
 - 8.14.3 Biotech Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
 - 8.14.4 Biotech Biologics and Biosimilars Product Portfolio
 - 8.14.5 Biotech Recent Developments
- 8.15 Gelgen
 - 8.15.1 Gelgen Company Information
 - 8.15.2 Gelgen Business Overview
 - 8.15.3 Gelgen Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
 - 8.15.4 Gelgen Biologics and Biosimilars Product Portfolio
 - 8.15.5 Gelgen Recent Developments
- 8.16 Innovent
 - 8.16.1 Innovent Company Information
 - 8.16.2 Innovent Business Overview
 - 8.16.3 Innovent Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)
 - 8.16.4 Innovent Biologics and Biosimilars Product Portfolio
 - 8.16.5 Innovent Recent Developments

8.17 Dong Bao

8.17.1 Dong Bao Company Information

8.17.2 Dong Bao Business Overview

8.17.3 Dong Bao Biologics and Biosimilars Sales, Value and Gross Margin
(2019-2024)

8.17.4 Dong Bao Biologics and Biosimilars Product Portfolio

8.17.5 Dong Bao Recent Developments

8.18 Ganlee

8.18.1 Ganlee Company Information

8.18.2 Ganlee Business Overview

8.18.3 Ganlee Biologics and Biosimilars Sales, Value and Gross Margin (2019-2024)

8.18.4 Ganlee Biologics and Biosimilars Product Portfolio

8.18.5 Ganlee Recent Developments

8.19 United Laboratories

8.19.1 United Laboratories Company Information

8.19.2 United Laboratories Business Overview

8.19.3 United Laboratories Biologics and Biosimilars Sales, Value and Gross Margin
(2019-2024)

8.19.4 United Laboratories Biologics and Biosimilars Product Portfolio

8.19.5 United Laboratories Recent Developments

9 VALUE CHAIN AND SALES CHANNELS ANALYSIS

9.1 Biologics and Biosimilars Value Chain Analysis

9.1.1 Biologics and Biosimilars Key Raw Materials

9.1.2 Raw Materials Key Suppliers

9.1.3 Manufacturing Cost Structure

9.1.4 Biologics and Biosimilars Sales Mode & Process

9.2 Biologics and Biosimilars Sales Channels Analysis

9.2.1 Direct Comparison with Distribution Share

9.2.2 Biologics and Biosimilars Distributors

9.2.3 Biologics and Biosimilars Customers

10 CONCLUDING INSIGHTS

11 APPENDIX

11.1 Reasons for Doing This Study

11.2 Research Methodology

11.3 Research Process

11.4 Authors List of This Report

11.5 Data Source

11.5.1 Secondary Sources

11.5.2 Primary Sources

List Of Tables

LIST OF TABLES

- Table 1. Biologics and Biosimilars Industry Trends
- Table 2. Biologics and Biosimilars Industry Drivers
- Table 3. Biologics and Biosimilars Industry Opportunities and Challenges
- Table 4. Biologics and Biosimilars Industry Restraints
- Table 5. Global Biologics and Biosimilars Revenue by Company (US\$ Million) & (2019-2024)
- Table 6. Global Biologics and Biosimilars Revenue Share by Company (2019-2024)
- Table 7. Global Biologics and Biosimilars Sales Volume by Company (K Units) & (2019-2024)
- Table 8. Global Biologics and Biosimilars Sales Volume Share by Company (2019-2024)
- Table 9. Global Biologics and Biosimilars Average Price (USD/Unit) of Company (2019-2024)
- Table 10. Global Biologics and Biosimilars Company Ranking, 2022 VS 2023 VS 2024 & (US\$ Million)
- Table 11. Global Biologics and Biosimilars Key Company Manufacturing Base & Headquarters
- Table 12. Global Biologics and Biosimilars Company, Product Type & Application
- Table 13. Global Biologics and Biosimilars Company Commercialization Time
- Table 14. Global Company Market Concentration Ratio (CR5 and HHI)
- Table 15. Global Biologics and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)
- Table 16. Mergers & Acquisitions, Expansion
- Table 17. Major Companies of Monoclonal Antibodies
- Table 18. Major Companies of Interferon
- Table 19. Major Companies of Erythropoietin
- Table 20. Major Companies of Insulin
- Table 21. Major Companies of Vaccines
- Table 22. Major Companies of Others
- Table 23. Global Biologics and Biosimilars Sales Volume by Type 2019 VS 2023 VS 2030 (K Units)
- Table 24. Global Biologics and Biosimilars Sales Volume by Type (2019-2024) & (K Units)
- Table 25. Global Biologics and Biosimilars Sales Volume by Type (2025-2030) & (K Units)

- Table 26. Global Biologics and Biosimilars Sales Volume Share by Type (2019-2024)
- Table 27. Global Biologics and Biosimilars Sales Volume Share by Type (2025-2030)
- Table 28. Global Biologics and Biosimilars Sales Value by Type 2019 VS 2023 VS 2030 (US\$ Million)
- Table 29. Global Biologics and Biosimilars Sales Value by Type (2019-2024) & (US\$ Million)
- Table 30. Global Biologics and Biosimilars Sales Value by Type (2025-2030) & (US\$ Million)
- Table 31. Global Biologics and Biosimilars Sales Value Share by Type (2019-2024)
- Table 32. Global Biologics and Biosimilars Sales Value Share by Type (2025-2030)
- Table 33. Major Companies of Tumor
- Table 34. Major Companies of Diabetes
- Table 35. Major Companies of Cardiovascular
- Table 36. Major Companies of Hemophilia
- Table 37. Major Companies of Others
- Table 38. Global Biologics and Biosimilars Sales Volume by Application 2019 VS 2023 VS 2030 (K Units)
- Table 39. Global Biologics and Biosimilars Sales Volume by Application (2019-2024) & (K Units)
- Table 40. Global Biologics and Biosimilars Sales Volume by Application (2025-2030) & (K Units)
- Table 41. Global Biologics and Biosimilars Sales Volume Share by Application (2019-2024)
- Table 42. Global Biologics and Biosimilars Sales Volume Share by Application (2025-2030)
- Table 43. Global Biologics and Biosimilars Sales Value by Application 2019 VS 2023 VS 2030 (US\$ Million)
- Table 44. Global Biologics and Biosimilars Sales Value by Application (2019-2024) & (US\$ Million)
- Table 45. Global Biologics and Biosimilars Sales Value by Application (2025-2030) & (US\$ Million)
- Table 46. Global Biologics and Biosimilars Sales Value Share by Application (2019-2024)
- Table 47. Global Biologics and Biosimilars Sales Value Share by Application (2025-2030)
- Table 48. Global Biologics and Biosimilars Sales by Region: 2019 VS 2023 VS 2030 (K Units)
- Table 49. Global Biologics and Biosimilars Sales by Region (2019-2024) & (K Units)
- Table 50. Global Biologics and Biosimilars Sales Market Share by Region (2019-2024)

- Table 51. Global Biologics and Biosimilars Sales by Region (2025-2030) & (K Units)
- Table 52. Global Biologics and Biosimilars Sales Market Share by Region (2025-2030)
- Table 53. Global Biologics and Biosimilars Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US\$ Million)
- Table 54. Global Biologics and Biosimilars Sales Value by Region (2019-2024) & (US\$ Million)
- Table 55. Global Biologics and Biosimilars Sales Value Share by Region (2019-2024)
- Table 56. Global Biologics and Biosimilars Sales Value by Region (2025-2030) & (US\$ Million)
- Table 57. Global Biologics and Biosimilars Sales Value Share by Region (2025-2030)
- Table 58. Global Biologics and Biosimilars Market Average Price (USD/Unit) by Region (2019-2024)
- Table 59. Global Biologics and Biosimilars Market Average Price (USD/Unit) by Region (2025-2030)
- Table 60. Global Biologics and Biosimilars Sales by Country: 2019 VS 2023 VS 2030 (K Units)
- Table 61. Global Biologics and Biosimilars Sales Value by Country: 2019 VS 2023 VS 2030 (US\$ Million)
- Table 62. Global Biologics and Biosimilars Sales by Country (2019-2024) & (K Units)
- Table 63. Global Biologics and Biosimilars Sales Market Share by Country (2019-2024)
- Table 64. Global Biologics and Biosimilars Sales by Country (2025-2030) & (K Units)
- Table 65. Global Biologics and Biosimilars Sales Market Share by Country (2025-2030)
- Table 66. Global Biologics and Biosimilars Sales Value by Country (2019-2024) & (US\$ Million)
- Table 67. Global Biologics and Biosimilars Sales Value Market Share by Country (2019-2024)
- Table 68. Global Biologics and Biosimilars Sales Value by Country (2025-2030) & (US\$ Million)
- Table 69. Global Biologics and Biosimilars Sales Value Market Share by Country (2025-2030)
- Table 70. Roche Company Information
- Table 71. Roche Business Overview
- Table 72. Roche Biologics and Biosimilars Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 73. Roche Biologics and Biosimilars Product Portfolio
- Table 74. Roche Recent Development
- Table 75. Amgen Company Information
- Table 76. Amgen Business Overview
- Table 77. Amgen Biologics and Biosimilars Sales (K Units), Value (US\$ Million), Price

(USD/Unit) and Gross Margin (2019-2024)

Table 78. Amgen Biologics and Biosimilars Product Portfolio

Table 79. Amgen Recent Development

Table 80. AbbVie Company Information

Table 81. AbbVie Business Overview

Table 82. AbbVie Biologics and Biosimilars Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 83. AbbVie Biologics and Biosimilars Product Portfolio

Table 84. AbbVie Recent Development

Table 85. Sanofi-Aventis Company Information

Table 86. Sanofi-Aventis Business Overview

Table 87. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 88. Sanofi-Aventis Biologics and Biosimilars Product Portfolio

Table 89. Sanofi-Aventis Recent Development

Table 90. Johnson & Johnson Company Information

Table 91. Johnson & Johnson Business Overview

Table 92. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 93. Johnson & Johnson Biologics and Biosimilars Product Portfolio

Table 94. Johnson & Johnson Recent Development

Table 95. Pfizer Company Information

Table 96. Pfizer Business Overview

Table 97. Pfizer Biologics and Biosimilars Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 98. Pfizer Biologics and Biosimilars Product Portfolio

Table 99. Pfizer Recent Development

Table 100. Novo Nordisk Company Information

Table 101. Novo Nordisk Business Overview

Table 102. Novo Nordisk Biologics and Biosimilars Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 103. Novo Nordisk Biologics and Biosimilars Product Portfolio

Table 104. Novo Nordisk Recent Development

Table 105. Eli Lilly Company Information

Table 106. Eli Lilly Business Overview

Table 107. Eli Lilly Biologics and Biosimilars Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 108. Eli Lilly Biologics and Biosimilars Product Portfolio

Table 109. Eli Lilly Recent Development

- Table 110. Novartis Company Information
- Table 111. Novartis Business Overview
- Table 112. Novartis Biologics and Biosimilars Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 113. Novartis Biologics and Biosimilars Product Portfolio
- Table 114. Novartis Recent Development
- Table 115. Merck Company Information
- Table 116. Merck Business Overview
- Table 117. Merck Biologics and Biosimilars Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 118. Merck Biologics and Biosimilars Product Portfolio
- Table 119. Merck Recent Development
- Table 120. 3sbio Company Information
- Table 121. 3sbio Business Overview
- Table 122. 3sbio Biologics and Biosimilars Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 123. 3sbio Biologics and Biosimilars Product Portfolio
- Table 124. 3sbio Recent Development
- Table 125. Changchun High Tech Company Information
- Table 126. Changchun High Tech Business Overview
- Table 127. Changchun High Tech Biologics and Biosimilars Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 128. Changchun High Tech Biologics and Biosimilars Product Portfolio
- Table 129. Changchun High Tech Recent Development
- Table 130. CP Guojian Company Information
- Table 131. CP Guojian Business Overview
- Table 132. CP Guojian Biologics and Biosimilars Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 133. CP Guojian Biologics and Biosimilars Product Portfolio
- Table 134. CP Guojian Recent Development
- Table 135. Biotech Company Information
- Table 136. Biotech Business Overview
- Table 137. Biotech Biologics and Biosimilars Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 138. Biotech Biologics and Biosimilars Product Portfolio
- Table 139. Biotech Recent Development
- Table 140. Gelgen Company Information
- Table 141. Gelgen Business Overview
- Table 142. Gelgen Biologics and Biosimilars Sales (K Units), Value (US\$ Million), Price

- (USD/Unit) and Gross Margin (2019-2024)
- Table 143. Gelgen Biologics and Biosimilars Product Portfolio
- Table 144. Gelgen Recent Development
- Table 145. Innovent Company Information
- Table 146. Innovent Business Overview
- Table 147. Innovent Biologics and Biosimilars Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 148. Innovent Biologics and Biosimilars Product Portfolio
- Table 149. Innovent Recent Development
- Table 150. Dong Bao Company Information
- Table 151. Dong Bao Business Overview
- Table 152. Dong Bao Biologics and Biosimilars Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 153. Dong Bao Biologics and Biosimilars Product Portfolio
- Table 154. Dong Bao Recent Development
- Table 155. Ganlee Company Information
- Table 156. Ganlee Business Overview
- Table 157. Ganlee Biologics and Biosimilars Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 158. Ganlee Biologics and Biosimilars Product Portfolio
- Table 159. Ganlee Recent Development
- Table 160. United Laboratories Company Information
- Table 161. United Laboratories Business Overview
- Table 162. United Laboratories Biologics and Biosimilars Sales (K Units), Value (US\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 163. United Laboratories Biologics and Biosimilars Product Portfolio
- Table 164. United Laboratories Recent Development
- Table 165. Key Raw Materials
- Table 166. Raw Materials Key Suppliers
- Table 167. Biologics and Biosimilars Distributors List
- Table 168. Biologics and Biosimilars Customers List
- Table 169. Research Programs/Design for This Report
- Table 170. Authors List of This Report
- Table 171. Secondary Sources
- Table 172. Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Biologics and Biosimilars Product Picture

Figure 2. Global Biologics and Biosimilars Sales Value (US\$ Million), 2019 VS 2023 VS 2030

Figure 3. Global Biologics and Biosimilars Sales Value (2019-2030) & (US\$ Million)

Figure 4. Global Biologics and Biosimilars Sales (2019-2030) & (K Units)

Figure 5. Global Biologics and Biosimilars Sales Average Price (USD/Unit) & (2019-2030)

Figure 6. Global Biologics and Biosimilars Company Revenue Ranking in 2023 (US\$ Million)

Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US\$ Million)

Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 9. Monoclonal Antibodies Picture

Figure 10. Interferon Picture

Figure 11. Erythropoietin Picture

Figure 12. Insulin Picture

Figure 13. Vaccines Picture

Figure 14. Others Picture

Figure 15. Global Biologics and Biosimilars Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 16. Global Biologics and Biosimilars Sales Volume Share 2019 VS 2023 VS 2030

Figure 17. Global Biologics and Biosimilars Sales Volume Share by Type (2019-2030)

Figure 18. Global Biologics and Biosimilars Sales Value by Type (2019 VS 2023 VS 2030) & (US\$ Million)

Figure 19. Global Biologics and Biosimilars Sales Value Share 2019 VS 2023 VS 2030

Figure 20. Global Biologics and Biosimilars Sales Value Share by Type (2019-2030)

Figure 21. Tumor Picture

Figure 22. Diabetes Picture

Figure 23. Cardiovascular Picture

Figure 24. Hemophilia Picture

Figure 25. Others Picture

Figure 26. Global Biologics and Biosimilars Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 27. Global Biologics and Biosimilars Sales Volume Share 2019 VS 2023 VS 2030

2030

Figure 28. Global Biologics an

I would like to order

Product name: Global Biologics and Biosimilars Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030

Product link: <https://marketpublishers.com/r/GD0577795DAEN.html>

Price: US\$ 4,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD0577795DAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

